Celcuity Förvaltning
Förvaltning kriterier kontrolleras 2/4
Celcuity VD är Brian Sullivan, utsedd i Jan 2012, har en mandatperiod på 14.67 år. totala årliga ersättningen är $ 16.37M, bestående av 3.5% lön 96.5% bonusar, inklusive företagsaktier och optioner. äger direkt 6.38% av företagets aktier, värda $ 266.81M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.7 år respektive 11.1 år.
Viktig information
Brian Sullivan
Verkställande direktör
US$16.4m
Total ersättning
| VD-lön i procent | 3.52% |
| Anställning som VD | 14.7yrs |
| Ägande av VD | 6.4% |
| Ledningens genomsnittliga anställningstid | 5.7yrs |
| Styrelsens genomsnittliga mandatperiod | 11.1yrs |
Senaste uppdateringar av ledningen
Recent updates
CELC: FDA Breast Cancer Approval Will Drive Commercial Launch Reappraisal
Celcuity's analyst price target has been adjusted from $165 to $178 as analysts factor in the recent Revtorpyk FDA approval, cleaner safety profile, and premium pricing potential into their updated launch and revenue assumptions. Analyst Commentary Recent research on Celcuity highlights how the Revtorpyk approval and updated clinical data are feeding into higher valuation frameworks, even as some analysts refine their models around study outcomes and safety profiles.
CELC: VIKTORIA-1 Data And Priority Review Will Drive Future Repricing
The updated analyst price target for Celcuity shifts to $145 from $94, reflecting how analysts are balancing recent VIKTORIA-1 efficacy and safety data with views on gedatolisib's competitive position and potential launch opportunities. Analyst Commentary Recent Street research on Celcuity reflects a mix of optimism about gedatolisib's potential and a more careful stance on execution risk following new VIKTORIA-1 data.
CELC: VIKTORIA Breast Cancer Data Will Drive Future Upside Potential
Celcuity's analyst price target has been raised from $116.70 to about $161.09, with analysts citing updated views on gedatolisib's efficacy, competitive positioning, and upcoming study readouts as key drivers behind the revision. Analyst Commentary Recent Street research on Celcuity shows a mix of optimism about gedatolisib's commercial prospects and caution around safety, competitive threats, and clinical nuances from the VIKTORIA-1 program.Priority FDA Review And Phase III Data Will Transform This Oncology Pure Play
Catalysts About Celcuity Celcuity is a clinical stage oncology company focused on developing gedatolisib, a targeted therapy for advanced breast and prostate cancers. What are the underlying business or industry changes driving this perspective?Single Drug Dependence And Heavy Financing Will Shape A Challenging Future
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Future Oncology Approvals And Pipeline Expansion Will Support A Stable Long Term Outlook
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
Summary Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million, supporting regulatory and commercial milestones. I maintain a long-term Buy rating on CELC, anticipating further upside as pivotal data, regulatory filings, and potential M&A activity unfold through 2027–2028. Read the full article on Seeking AlphaIs Celcuity (NASDAQ:CELC) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Summary Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in combination therapies for advanced breast cancer, with significant ORR and mPFS improvements. Financially, Celcuity has a strong cash position and secured funding, ensuring a runway through 2026, despite patent expiration risks. Despite Stifel's buy rating and blockbuster potential, the risk-reward profile of CELC remains unattractive at this stage. Read the full article on Seeking AlphaIs Celcuity (NASDAQ:CELC) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Summary Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks. Read the full article on Seeking AlphaDoes Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$226m |
| Mar 31 2026 | n/a | n/a | -US$193m |
| Dec 31 2025 | US$16m | US$577k | -US$177m |
| Sep 30 2025 | n/a | n/a | -US$163m |
| Jun 30 2025 | n/a | n/a | -US$149m |
| Mar 31 2025 | n/a | n/a | -US$127m |
| Dec 31 2024 | US$7m | US$525k | -US$112m |
| Sep 30 2024 | n/a | n/a | -US$94m |
| Jun 30 2024 | n/a | n/a | -US$83m |
| Mar 31 2024 | n/a | n/a | -US$73m |
| Dec 31 2023 | US$2m | US$210k | -US$64m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$2m | US$106k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$36m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$1m | US$260k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$22m |
| Mar 31 2021 | n/a | n/a | -US$10m |
| Dec 31 2020 | US$469k | US$250k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$992k | US$250k | -US$7m |
Ersättning vs marknad: Brian s total kompensation ($USD 16.37M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 6.88M ).
Ersättning vs inkomst: Ersättningen för Brian har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Brian Sullivan (64 yo)
Mr. Brian F. Sullivan is the Co-Founder of Celcuity Inc. and has been its Chairman and Chief Executive Officer since 2012 and served as its Chief Financial Officer. Mr. Sullivan Co-founded Entegris, Inc. i...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 14.7yrs | US$16.37m | 6.38% $ 266.8m | |
| Co-Founder | 14.7yrs | US$4.19m | 2.56% $ 106.9m | |
| Chief Financial Officer | 9.2yrs | US$3.41m | 0.045% $ 1.9m | |
| Head of Investor Relations & Corporate Communications | no data | inga uppgifter | inga uppgifter | |
| General Counsel | 1.9yrs | inga uppgifter | inga uppgifter | |
| Acting Head of Clinical Operations | 5.7yrs | inga uppgifter | inga uppgifter | |
| Chief Medical Officer | 4.5yrs | inga uppgifter | inga uppgifter | |
| Chief Commercial Officer | 2.6yrs | inga uppgifter | inga uppgifter |
Erfaren ledning: CELC s ledningsgrupp är erfaren och erfaren ( 5.7 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 14.7yrs | US$16.37m | 6.38% $ 266.8m | |
| Co-Founder | 14.7yrs | US$4.19m | 2.56% $ 106.9m | |
| Independent Director | 9.7yrs | US$140.00k | 0.16% $ 6.8m | |
| Independent Director | 12.6yrs | US$140.00k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$140.00k | 0.022% $ 940.4k | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Scientific Advisory Board | 7.7yrs | inga uppgifter | inga uppgifter |
Erfaren styrelse: CELC s styrelse är rutinerade och erfaren ( 11.1 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/11 02:36 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Celcuity Inc. bevakas av 17 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |